Alvotech (ALVO)
NASDAQ: ALVO · IEX Real-Time Price · USD
14.15
+0.50 (3.66%)
At close: Apr 26, 2024, 4:00 PM
14.23
+0.08 (0.57%)
After-hours: Apr 26, 2024, 5:56 PM EDT
Alvotech Revenue
In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth. Revenue in the quarter ending December 31, 2023 was $55.28M with 115.53% year-over-year growth.
Revenue (ttm)
$93.38M
Revenue Growth
+9.84%
P/S Ratio
40.43
Revenue / Employee
$91,016
Employees
1,026
Market Cap
3.78B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | 82.68M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Select Medical Holdings | 6.66B |
| PACS Group | 3.11B |
| Envista Holdings | 2.57B |
| Alkermes | 1.66B |
| RadNet | 1.62B |
| Integer Holdings | 1.60B |
| iRhythm Technologies | 492.68M |
| Ultragenyx Pharmaceutical | 434.25M |
ALVO News
- 2 days ago - Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) - GlobeNewsWire
- 7 days ago - Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) - GlobeNewsWire
- 10 days ago - Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) - Business Wire
- 23 days ago - Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 - GlobeNewsWire
- 5 weeks ago - Alvotech Announces Increase in Number of Own Shares - GlobeNewsWire
- 5 weeks ago - Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update - GlobeNewsWire
- 7 weeks ago - Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET - GlobeNewsWire
- 2 months ago - Alvotech Appoints Interim Chief Quality Officer - GlobeNewsWire